The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 awarded Myriad Genetic Laboratories Inc. a blanket purchase agreement to provide Prolaris prostate cancer testing services. Three firm fixed price call contracts were placed against the BPA between 2021 and 2024, with a combined value of $74,970. As the prime, Myriad will deliver the genomic testing to the VA Salt Lake City Health Care System in Utah. This testing assists with disease risk stratification and treatment planning for veterans served by VISN 19.
The BPA and associated call contracts aim to procure Prolaris prostate cancer testing services for veterans within the network through April 2026. Testing will be conducted at the Salt Lake City, Utah location by Myriad Genetic Laboratories as the prime contractor. A no set-aside was used for these awards to Myriad Genetics Inc.'s subsidiary to support prostate cancer screening, diagnosis, and care for patients within the VA network.
Generated 1/4/24, 5:40 PM